Abstract: Objective To investigate the clinical value of estrogen and combined detection with common lung cancer biomarkers in the diagnostic efficiency of male lung cancer patients.Methods This study included 141 male patients with lung disease who have tested the serum E2 level between January,2019 and May,2021.The serum levels of carcinoembryonic antigen (CEA),cancer antigen 125 (CA125) and neuron specific enolase (NSE) were measured and statistically analyzed for comparing with estrogen.Results The study included 28 patients with benign lung lesions (BPL) and 113 patients with lung cancer.The results showed that the level of E2 in patients with lung cancer was significantly increased (P=0.003 4) and positively correlated with TNM staging (P=0.002 2).Patients with stage Ⅰ~Ⅱ and N0-N1 showed a decline in E2 postoperatively,while most patients with stage Ⅲ~Ⅳ and N2 showed an increase in E2 level after surgery.With BPL group as control,E2 showed the highest sensitivity and accuracy in the diagnosis of lung cancer compared with CEA,CA125 and NSE.Combined detection of E2,CEA and CA125 showed the best diagnostic ability (AUC=0.837).Conclusions Estrogen is a potential biomarker for the diagnosis of male lung cancer.

Key words: estrogen, lung cancer, diagnose, biomarkers